BRPI0921782A2 - antagonistas da via hedgehog de piridazina tetrassubstituída - Google Patents

antagonistas da via hedgehog de piridazina tetrassubstituída

Info

Publication number
BRPI0921782A2
BRPI0921782A2 BRPI0921782A BRPI0921782A BRPI0921782A2 BR PI0921782 A2 BRPI0921782 A2 BR PI0921782A2 BR PI0921782 A BRPI0921782 A BR PI0921782A BR PI0921782 A BRPI0921782 A BR PI0921782A BR PI0921782 A2 BRPI0921782 A2 BR PI0921782A2
Authority
BR
Brazil
Prior art keywords
hedgehog pathway
pathway antagonists
tetrasubstituted
tetrasubstituted pyridazine
pyridazine hedgehog
Prior art date
Application number
BRPI0921782A
Other languages
English (en)
Portuguese (pt)
Inventor
Jon Sall Daniel
Daniel Cohen Jeffrey
Anne Bastian Jolie
Marie Clay Julia
Lynn Lobb Karen
Lee Thompson Michelle
Arthur Hipskind Philip
Wilson Takako (Nee Takakuwa)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of BRPI0921782A2 publication Critical patent/BRPI0921782A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
BRPI0921782A 2008-11-17 2009-11-05 antagonistas da via hedgehog de piridazina tetrassubstituída BRPI0921782A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11533208P 2008-11-17 2008-11-17
PCT/US2009/063370 WO2010056588A1 (en) 2008-11-17 2009-11-05 Tetrasubstituted pyridazine hedgehog pathway antagonists

Publications (1)

Publication Number Publication Date
BRPI0921782A2 true BRPI0921782A2 (pt) 2019-09-24

Family

ID=41722877

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0921782A BRPI0921782A2 (pt) 2008-11-17 2009-11-05 antagonistas da via hedgehog de piridazina tetrassubstituída

Country Status (18)

Country Link
US (1) US8507490B2 (enExample)
EP (1) EP2358698B1 (enExample)
JP (1) JP5518887B2 (enExample)
KR (1) KR101342184B1 (enExample)
CN (1) CN102216285B (enExample)
AU (1) AU2009314349B2 (enExample)
BR (1) BRPI0921782A2 (enExample)
CA (1) CA2743483C (enExample)
CY (1) CY1113377T1 (enExample)
DK (1) DK2358698T3 (enExample)
EA (1) EA017386B1 (enExample)
ES (1) ES2392759T3 (enExample)
HR (1) HRP20120762T1 (enExample)
MX (1) MX2011005177A (enExample)
PL (1) PL2358698T3 (enExample)
PT (1) PT2358698E (enExample)
SI (1) SI2358698T1 (enExample)
WO (1) WO2010056588A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0714872A2 (pt) * 2006-07-17 2013-03-19 Syngenta Participations Ag derivados de piridazina
CN102066353B (zh) 2008-04-29 2013-12-11 伊莱利利公司 二取代的酞嗪Hedgehog通路拮抗剂
ES2418479T3 (es) 2008-11-03 2013-08-14 Eli Lilly And Company Antagonistas de la ruta erizo de ftalazinas disustituidas
JP5518088B2 (ja) 2008-11-17 2014-06-11 イーライ リリー アンド カンパニー 四置換ピリダジンヘッジホッグ経路アンタゴニスト
AR077014A1 (es) 2009-06-19 2011-07-27 Lilly Co Eli Compuesto derivado de ftalazina 1,4-disustituida, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para el tratamiento de cancer
GB201309508D0 (en) 2013-05-28 2013-07-10 Redx Pharma Ltd Compounds
US9814703B2 (en) 2013-11-14 2017-11-14 The Board Of Trustees Of The Leland Stanford Junior University Methods for treating cancer by activation of BMP signaling
GB2528298A (en) * 2014-07-16 2016-01-20 Redx Pharma Plc Compounds
CN105130980B (zh) * 2015-09-09 2018-05-22 沈阳药科大学 N-3-苯并咪唑噻唑胺类衍生物及其制备方法与应用
CN107163028B (zh) * 2017-05-24 2019-07-12 东南大学 一种苯甲酰胺类Hedgehog抑制剂及其制备方法和应用
CN110208424A (zh) * 2019-06-28 2019-09-06 江苏恒生检测有限公司 一种农药氟啶虫酰胺中含有杂质的分析方法
WO2021071981A1 (en) * 2019-10-08 2021-04-15 Skyhawk Therapeutics, Inc. Compounds for modulating splicing
US12605377B2 (en) 2020-10-13 2026-04-21 Endeavor Biomedicines, Inc. Methods of treating fibrosis
JP7868066B2 (ja) 2020-10-13 2026-06-01 エンデバー バイオメディシンズ， インコーポレイテッド 線維症を処置する方法
US20250333397A1 (en) * 2021-08-30 2025-10-30 Remix Therapeutics Inc. Compounds and methods for modulating splicing
US12447148B2 (en) 2024-03-05 2025-10-21 Endeavor Biomedicines, Inc. Methods of improving lung function

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1293565A (en) 1969-05-03 1972-10-18 Aspro Nicholas Ltd Aminophthalazines and pharmaceutical compositions thereof
AU717744B2 (en) 1996-01-15 2000-03-30 Janssen Pharmaceutica N.V. Angiogenesis inhibiting pyridazinamines
US6432970B2 (en) 1998-04-09 2002-08-13 Johns Hopkins University School Of Medicine Inhibitors of hedgehog signaling pathways, compositions and uses related thereto
JP5067986B2 (ja) 1998-04-09 2012-11-07 ジョンズ ホプキンズ ユニヴァーシティー スクール オブ メディシン ヘッジホッグシグナリング経路の阻害剤としてのステロイドアルカロイド誘導体の使用
GB0013674D0 (en) 1999-06-08 2000-07-26 Lorantis Ltd Therapeutic use
AU2003231032B2 (en) 2002-04-22 2008-07-10 Johns Hopkins University School Of Medicine Modulators of hedgehog signaling pathways, compositions and uses related thereto
AU2003265853A1 (en) 2002-08-29 2004-03-19 Curis, Inc. Hedgehog antagonists, methods and uses related thereto
WO2005033288A2 (en) 2003-09-29 2005-04-14 The Johns Hopkins University Hedgehog pathway antagonists
WO2005080378A1 (ja) 2004-02-24 2005-09-01 Mitsubishi Pharma Corporation 縮合ピリダジン誘導体
EP1745039A4 (en) 2004-05-08 2009-07-22 Neurogen Corp 3-ARYL-5,6-DISUBSTITUTED PYRIDAZINES
WO2006028958A2 (en) 2004-09-02 2006-03-16 Genentech, Inc. Pyridyl inhibitors of hedgehog signalling
EP1900731A1 (de) 2006-09-07 2008-03-19 Bayer Schering Pharma Aktiengesellschaft N-(1-Phthalazin-1-yl-piperidin-4-yl)-amide als EP2-Rezeptor Modulatoren
US8536168B2 (en) 2007-03-15 2013-09-17 Novartis Ag Benzyl and pyridinyl derivatives as modulators of the hedgehog signaling pathway
US8153633B2 (en) 2007-06-25 2012-04-10 Amgen Inc. Phthalazine compounds, compositions and methods of use
AU2008300019A1 (en) 2007-09-07 2009-03-19 Amgen Inc. Annelated pyridazines for the treatment of tumors driven by inappropriate hedgehog signalling
CN102066353B (zh) 2008-04-29 2013-12-11 伊莱利利公司 二取代的酞嗪Hedgehog通路拮抗剂
US20100041663A1 (en) 2008-07-18 2010-02-18 Novartis Ag Organic Compounds as Smo Inhibitors
ES2418479T3 (es) 2008-11-03 2013-08-14 Eli Lilly And Company Antagonistas de la ruta erizo de ftalazinas disustituidas
JP5518088B2 (ja) 2008-11-17 2014-06-11 イーライ リリー アンド カンパニー 四置換ピリダジンヘッジホッグ経路アンタゴニスト
AR077014A1 (es) 2009-06-19 2011-07-27 Lilly Co Eli Compuesto derivado de ftalazina 1,4-disustituida, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para el tratamiento de cancer

Also Published As

Publication number Publication date
US8507490B2 (en) 2013-08-13
AU2009314349A1 (en) 2010-05-20
HRP20120762T1 (hr) 2012-10-31
CA2743483A1 (en) 2010-05-20
CN102216285B (zh) 2014-08-13
DK2358698T3 (da) 2012-10-08
MX2011005177A (es) 2011-05-30
KR101342184B1 (ko) 2013-12-19
AU2009314349B2 (en) 2013-04-18
JP5518887B2 (ja) 2014-06-11
PL2358698T3 (pl) 2013-01-31
KR20110070920A (ko) 2011-06-24
PT2358698E (pt) 2012-10-24
EP2358698B1 (en) 2012-09-05
ES2392759T3 (es) 2012-12-13
US20110263602A1 (en) 2011-10-27
CY1113377T1 (el) 2016-06-22
WO2010056588A1 (en) 2010-05-20
EP2358698A1 (en) 2011-08-24
SI2358698T1 (sl) 2012-11-30
EA201170699A1 (ru) 2011-12-30
JP2012509263A (ja) 2012-04-19
CA2743483C (en) 2014-03-11
EA017386B1 (ru) 2012-12-28
CN102216285A (zh) 2011-10-12

Similar Documents

Publication Publication Date Title
BRPI0921777A2 (pt) antagonistas da via hedgehog de piridazina tetrassubstituída
EP3270564C0 (en) DISTRIBUTED SECURITY PROVISION
BRPI0911618A2 (pt) antagonistas da via hedgehog de ftalazina dissubstituída.
BRPI1008749A2 (pt) Derivados de benzodiazepina
SI2358698T1 (sl) Tetrasubstituiran piridazin kot antagonist signalne poti hedgehog
BRPI0817601A2 (pt) dispositivos de segurança
BRPI0920521A2 (pt) combinação farmacêutica
BRPI0921327A2 (pt) Combinação de herbicida-protetor
BRPI0909656A2 (pt) Microencapsulamento
BRPI0908116A2 (pt) pulverizador
BRPI0914743A2 (pt) estrutura
BRPI0813843A2 (pt) Contactor
HRP20180429T1 (hr) Raspršivač
BRPI0907952A2 (pt) Combinação de vitamina d e 25-hidroxivitamina d3
BRPI0921437A2 (pt) antagonistas da via do hedgehog á base de fitalazina dissubstituída
ES1067502Y (es) Columbario modular
BRPI0821498A2 (pt) Estrutura de queimador
BRPI0923550A2 (pt) penico
BRPI0922728A2 (pt) combinação de herbicida-antídoto
FI20085899A0 (fi) Puu-Metalli-komposiittirakenne
EP2268182A4 (en) JET
DK2323933T3 (da) Stableenhed
DK2277578T3 (da) Forstøver
FI20085651A0 (fi) Palonsammutusjärjestelmä
DE112009001669A5 (de) Sektionaltor

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.